MedTrace Logo

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035

NCT02690142 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2018-03-02

No results posted yet for this study

Summary

The purpose of this first-in-human study is to investigate the safety and tolerability of ABY-035 when administered intravenously and subcutaneously, to healthy volunteers and to psoriasis patients.

Conditions

Interventions

DRUG

Placebo

Single dose i.v.

DRUG

ABY-035 i.v.

Single dose i.v.

DRUG

ABY-035 s.c.

Single dose s.c.

Sponsors & Collaborators

  • Covance

    collaborator INDUSTRY

  • Affibody

    lead INDUSTRY

Principal Investigators

  • Sunu Valasseri, MBBS, MSc · Covance Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-01-10
Completion
2018-01-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02690142 on ClinicalTrials.gov